Tilray Medical expands its Tilray Craft portfolio in Germany with five new EU-GMP certified cannabis flower products.
Quiver AI Summary
Tilray Medical, a division of Tilray Brands, announced the expansion of its Tilray Craft portfolio in Germany, introducing five new EU-GMP certified cannabis flower products cultivated in its Neumünster facility. These additions reflect Tilray's commitment to providing a diverse range of quality medical cannabis options for patients, physicians, and pharmacies as part of the BfArM in-country cultivation program. Rajnish Ohri, Managing Director International, emphasized the company's dedication to patient care and highlighted the rigorous quality control processes in place to ensure consistency and reliability. The new products, which include varieties with high THC levels, are available by prescription throughout Germany, showcasing Tilray's focus on advancing medical cannabis innovation to meet evolving patient needs.
Potential Positives
- Expansion of the Tilray Craft portfolio with five new EU-GMP certified cannabis flower products enhances product offerings in Germany, supporting patient care and accessibility.
- Production in an EU-GMP certified facility ensures high-quality, consistent medical cannabis, which aligns with rigorous pharmaceutical standards.
- Commitment to providing tailored medical cannabis options through ongoing innovation, addressing the evolving needs of patients and healthcare professionals.
Potential Negatives
- Expansion of product offerings may not translate to increased sales due to a competitive and evolving market for medical cannabis in Germany.
- The reliance on forward-looking statements creates uncertainty regarding the company's future performance and ability to meet its commitments.
- Potential risks and uncertainties mentioned may raise concerns for investors about the stability and reliability of the company's projections.
FAQ
What products are included in the new Tilray Craft portfolio expansion?
The expansion includes five new cannabis flower products: THC30 TRM, THC28 TRM, THC28 PPV, THC25 PPV, and THC22 SNS.
Where are Tilray Craft cannabis products produced?
Tilray Craft cannabis is produced at Tilray’s EU-GMP certified facility located in Neumünster, Germany.
How can patients access Tilray Craft products?
All Tilray Craft products are available by prescription at pharmacies throughout Germany.
What does EU-GMP certification ensure?
EU-GMP certification ensures that the cannabis products meet rigorous quality control standards for safety and reliability.
What is Tilray's mission in the medical cannabis sector?
Tilray's mission is to provide safe and reliable access to a global portfolio of medical cannabis brands for patients in need.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TLRY Insider Trading Activity
$TLRY insiders have traded $TLRY stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TLRY stock by insiders over the last 6 months:
- IRWIN D SIMON (President and CEO) purchased 165,000 shares for an estimated $100,105
- CARL A MERTON (Chief Financial Officer) purchased 33,500 shares for an estimated $19,939
- MITCHELL GENDEL (Global General Counsel) purchased 6,000 shares for an estimated $3,496
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TLRY Hedge Fund Activity
We have seen 107 institutional investors add shares of $TLRY stock to their portfolio, and 131 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 5,239,802 shares (+1667.9%) to their portfolio in Q2 2025, for an estimated $2,171,373
- TIDAL INVESTMENTS LLC added 3,776,410 shares (+15.0%) to their portfolio in Q2 2025, for an estimated $1,564,944
- BANK OF MONTREAL /CAN/ removed 2,478,386 shares (-91.5%) from their portfolio in Q2 2025, for an estimated $1,027,043
- ARISTEIA CAPITAL, L.L.C. removed 2,436,913 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,009,856
- LUXOR CAPITAL GROUP, LP added 2,343,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $970,939
- AUSDAL FINANCIAL PARTNERS, INC. added 2,265,416 shares (+inf%) to their portfolio in Q2 2025, for an estimated $938,788
- JANE STREET GROUP, LLC added 2,233,480 shares (+1583.1%) to their portfolio in Q2 2025, for an estimated $925,554
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TLRY Price Targets
Multiple analysts have issued price targets for $TLRY recently. We have seen 2 analysts offer price targets for $TLRY in the last 6 months, with a median target of $1.5.
Here are some recent targets:
- Kaumil Gajrawala from Jefferies set a target price of $2.0 on 08/25/2025
- Michael Lavery from Piper Sandler set a target price of $1.0 on 04/09/2025
Full Release
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray’s EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The additions reflect Tilray’s ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU‑GMP certified medical cannabis options for eligible patients.
Rajnish Ohri, Managing Director International at Tilray Brands, commented, “The expansion of our Tilray Craft premium cannabis flower range demonstrates our commitment to patient care in Germany. As a global leader in medical cannabis, supported by our advanced EU-GMP facility in Germany, Tilray continuously introduces new genetics bred to pharmaceutical standards at Neumünster. This approach enables us to provide reliable, patient-focused medical cannabis options. Our priority remains delivering consistent, quality solutions to physicians and pharmacies, always placing patients' needs first.”
Tilray Craft cannabis is cultivated and produced indoors at Tilray’s EU‑GMP certified facility located in Neumünster, Germany. The production process adheres to rigorous quality control standards and protocols, ensuring distinctive, quality medical cannabis that patients can depend on for consistency and reliability.
New Tilray Craft Products:
- Tilray Craft Cannabisblüten THC30 TRM (Triangle Mints)
- Tilray Craft Cannabisblüten THC28 TRM (Triangle Mints)
- Tilray Craft Cannabisblüten THC28 PPV (Platinum Pave 34)
- Tilray Craft Cannabisblüten THC25 PPV (Platinum Pave 34)
-
Tilray Craft Cannabisblüten THC22 SNS (Sunset Sherbet)
All Tilray Craft products are available by prescription at pharmacies throughout Germany. Tilray remains dedicated to advancing medical cannabis innovation and supporting healthcare professionals with quality, compliant solutions. As patient needs continue to evolve, the company will responsibly expand its portfolio to ensure access to consistent, EU-GMP certified products both within Germany and internationally.
About Tilray Craft
Tilray Craft is next-level quality. It’s our specialist range of high potency flower exclusive to German patients. Indoor-grown in Neumünster, we focus on precision, optimising every stage of the process so that we bring patients only our very best buds. Combined with carefully selected, high THC, unique terpene genetics, Tilray Craft is fast becoming the medical cannabis brand of choice for higher-strength therapy needs.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Tilray Craft, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is a leading supplier of medical cannabis with a portfolio of brands and products designed to meet the needs of our patients worldwide.
For further information on Tilray Medical, visit Tilray Medical Europe , Tilray Medical Canada , and Tilray Medical Australia-New Zealand .
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media:
[email protected]
Investor Relations:
[email protected]